Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | PRKCA | P17252 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9250546 | 0.93 | GPR84 (0.47) | ALDH1A1CA1GPR84FFAR1PRKCA | |
| SCHEMBL11785027 | 0.91 | GPR84 (0.50) | GPR84FFAR1PRKCAFAAH | |
| SCHEMBL11782571 | 0.91 | GPR84 (0.50) | GPR84FFAR1PRKCAFAAH | |
| SCHEMBL8666568 | 0.91 | GPR84 (0.50) | GPR84FFAR1PRKCAFAAH | |
| SCHEMBL11784604 | 0.91 | GPR84 (0.50) | GPR84FFAR1PRKCAFAAH | |
| SCHEMBL11782858 | 0.91 | GPR84 (0.50) | GPR84FFAR1PRKCAFAAH | |
| SCHEMBL6468137 | 0.91 | GPR84 (0.50) | GPR84FFAR1PRKCAFAAH | |
| SCHEMBL11778914 | 0.91 | GPR84 (0.50) | GPR84FFAR1PRKCAFAAH | |
| SCHEMBL11782957 | 0.91 | GPR84 (0.50) | GPR84FFAR1PRKCAFAAH | |
| Methoxymethane SCHEMBL3379495 | 0.90 | GPR84 (0.44) | CA1GPR84FFAR1PRKCAFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350022-B1 | NEW BENZIMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2013-11-20 | — | — | EP | disclosed |
| EP-2222645-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | HOFFMANN LA ROCHE (CH) | 2013-03-20 | — | — | EP | disclosed |
| US-8242280-B2 | morpholin-4-yl-{3-[3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl-phenyl}-methanone; FMS-like tyrosine kinase 3 (FLT3), is implicated in cancers, including leukemia, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia | SGX PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8143422-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2350022-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-08-03 | — | — | EP | disclosed |
| US-7825258-B2 | Methyl-benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-11-02 | — | — | US | disclosed |
| EP-2222645-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2010-09-01 | — | — | EP | disclosed |
| WO-2010043513-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-22 | — | — | WO | disclosed |
| US-20100093818-A1 | BENZIMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-04-15 | — | — | US | disclosed |
| EP-2078020-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2009-07-15 | — | — | EP | disclosed |
| WO-2009062874-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131482-A1 | METHYL-BENZIMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-05-21 | — | — | US | disclosed |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2008124848-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-5132452-A | Platinum or palladium catalyst with bismuth in an alkaline solution supported on charcoal | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1992-07-21 | — | — | US | disclosed |
| EP-0151498-B1 | PROCESS FOR THE PREPARATION OF 2-KETO-ALDONIC ACIDS | AKZO N.V. (NL) | 1989-04-19 | — | — | EP | disclosed |
| US-4620034-A | Process for the preparation of 2-keto-aldonic acids | AKZO NV (NL) | 1986-10-28 | — | — | US | disclosed |
| EP-0151498-A2 | Process for the preparation of 2-keto-aldonic acids | AKZO N.V. (NL) | 1985-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | MAP3K20, MAP3K19, MAP4K2 | ALDH1A1 4191/4885CA2 4141/4885CA1 4824/4885 |
| US-20090131482-A1 | METHYL-BENZIMIDAZOLE DERIVATIVES | HDAC10, CYP3A4, ECI1 | ALDH1A1 154/4885CA2 1058/4885CA1 4270/4885 |
| US-20100093818-A1 | BENZIMIDAZOLE DERIVATIVES | CYP2B6, CYP3A4, CYP2C19 | ALDH1A1 57/4885CA2 1174/4885CA1 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.